Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), June Weon Cheong, Árpád Illés(University of Debrecen), Tatyana Feldman(Hackensack University Medical Center), Sam Yuen(Calvary Mater Newcastle Hospital), Angelo Michele Carella(San Antonio College), Kerry J. Savage(Spinal Cord Injury BC), Luca Arcaini(University of Pavia), Eva Domingo‐Doménech, Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Su‐Peng Yeh(China Medical University), Kensei Tobinai(National Cancer Center), Joseph Woolery(Seagen (United States)), Kunihiro Tsukasaki(Nagasaki University), Naresh Bellam(University of Alabama at Birmingham), Franck Morschhauser(Hôpital Claude Huriez), Javier Briones(Hospital de Sant Pau), Fabio Benedetti(Azienda Ospedaliera Universitaria Integrata Verona), Andrei R. Shustov(Seattle Cancer Care Alliance), Ranjana H. Advani(Stanford Medicine), David M. Aboulafia(Virginia Mason Medical Center), David Belada(Charles University), Luca Baldini(University of Milan), Won Seog Kim(Samsung Medical Center), Nancy L. Bartlett(Washington University in St. Louis), Tim Illidge(Manchester Academic Health Science Centre), Andreas Hüttmann(University of Duisburg-Essen), Dina Ben Yehuda(Hadassah Medical Center), Peter Borchman, Michelle A. Fanale(Pfizer (United States)), Önder Alpdoğan(Thomas Jefferson University), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Dominique Bordessoule(Centre Hospitalier Universitaire de Limoges), Giuseppe Rossi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Hung Chang, Kiyoshi Ando(Hiroshima University), Meredith Little(Takeda (United States)), Shangbang Rao(Seagen (United States)), Jacob Haaber Christensen(Odense University Hospital), Zhaowei Hua(Takeda (United States)), Anne Lennard, Thomas Manley(IGM Biosciences (United States)), Pauline Brice(Hôpital de Jolimont), Dolores Caballero(Complejo Hospitalario de Salamanca), Owen A. O’Connor(Virginia Cancer Institute), Lorenz Trümper(University of Göttingen), Barbara Pro(The University of Texas MD Anderson Cancer Center)
Cited by 733
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k